News

Our Healthcare News

Revance Appoints Mark Foley to its Board of Directors

NEWARK, California—Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that Mark Foley…  

Sep 06 2017

IntegenX Applauds the Passage of the Rapid DNA Act of 2017

Pleasanton, California – – IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The…  

Aug 17 2017

AxoGen, Inc Reports 2017 Second Quarter Financial Results, Representing 46% Growth over Prior Year

ALACHUA, Fla., (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and…  

Aug 02 2017

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year

DANVERS, Massachusetts—  Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an…  

Jul 27 2017

Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities

TORONTO, Canada—Venus Concept Ltd., a privately-held and innovative global aesthetic technology leader, today announced the closing of a $38 million equity investment. The equity investment…  

Jul 13 2017

EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for First-Line Treatment

HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the…  

Jun 23 2017

Centers for Medicare/Medicaid Services Establishes Coding and Payment for Eustachian Tube Balloon

PLYMOUTH, Minnesota—Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive…  

May 22 2017

Revance Announces Positive Results in RT002 Injectable Phase 2 Cervical Dystonia Trial

NEWARK, Calif.——Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced duration of effect…  

May 18 2017

Endologix Provides an Update on the Nellix Endovascular Aneurysm Sealing System US Regulatory Status

IRVINE, California – Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the…  

May 17 2017